Journal: Small (Weinheim an der Bergstrasse, Germany)

Article Title: Molecular Imaging Using Nanoparticle Quenchers of Cerenkov Luminescence

doi: 10.1002/smll.201400733

Figure Lengend Snippet: Nanoparticle quenching of Cerenkov Luminescence. (A) CL can be produced by charged particles, for example those produced upon decay of PET-radionuclides, traveling at high speed through biological media. (B) Radionuclides at the disease site can produce detectable CL; for example [18F]-FDG uptake by tumor cells. With nanoparticle colocalization through enhanced permeability and retention or targeted nanoparticle absorbers the CL signal is quenched. This enables dual readout of disease biology with non-invasive diagnostic imaging tools that are currently in wide-spread use.

Article Snippet: Nanoparticle Probes Ferumoxyol (Feraheme; AMAG Pharmaceuticals, Inc.) was used as provided.

Techniques: Produced, Permeability, Diagnostic Assay, Imaging

Journal: Small (Weinheim an der Bergstrasse, Germany)

Article Title: Molecular Imaging Using Nanoparticle Quenchers of Cerenkov Luminescence

doi: 10.1002/smll.201400733

Figure Lengend Snippet: Cerenkov Quenching with Clinical Applied Materials. (A) Chemical structure of the patent blue dye Lymphazurin, used for sentinel lymph node imaging. (B) CL profile and absorption spectra of [18F]-FDG and patent blue dye, respectively. (C,D) Dose-dependent quenching of CL signal by Lymphazurin; PET signal remains unaffected. (E) Schematic of iron oxide nanoparticle, modification with fluorescent dyes. (F) CL profile of [18F]-FDG and absorption spectra of the FDA-approved ferumoxytol and the research grade Cy5.5-SPIO. (G,H) Again, a concentration gradient of the ferumoxytol produces a change in the amount of the CL signal produced, while PET signal remains constant. MIP, mean intensity projection of the tomographic PET dataset. Photon counts are counts/sec; Radiance units are photons/cm2/sr/sec.

Article Snippet: Nanoparticle Probes Ferumoxyol (Feraheme; AMAG Pharmaceuticals, Inc.) was used as provided.

Techniques: Imaging, Modification, Concentration Assay, Produced

Journal: Small (Weinheim an der Bergstrasse, Germany)

Article Title: Molecular Imaging Using Nanoparticle Quenchers of Cerenkov Luminescence

doi: 10.1002/smll.201400733

Figure Lengend Snippet: In vivo Quenching of Cerenkov Luminescence with Iron Oxide Nanoparticles. The ferumoxytol analog, fluorescently labeled crosslinked iron oxide (Cy5.5-SPIO), or phosphate buffered saline (control) were administered to HT1080 tumor bearing mice. (A) Conventional fluorescent imaging of the Cy5.5 label (external excitation, color-coded in red) was used to follow probe accumulation. Food, green. (B) Following 24 h of nanoparticle uptake, [18F]-FDG (14.8 MBq) was administered. Representative PET scans show equivalent tumor uptake. (C) The CL scans reveal differences in the light emitted from each tumor. There is greater light output from the PBS control injected mice. B; Bladder. (D) PET quantitation reveals no difference in [18F]-FDG uptake. (E) However, the Cerenkov luminescence detected in the tumors of mice given the Cy5.5-SPIO was significantly attenuated.

Article Snippet: Nanoparticle Probes Ferumoxyol (Feraheme; AMAG Pharmaceuticals, Inc.) was used as provided.

Techniques: In Vivo, Labeling, Saline, Control, Imaging, Injection, Quantitation Assay

Journal: Small (Weinheim an der Bergstrasse, Germany)

Article Title: Molecular Imaging Using Nanoparticle Quenchers of Cerenkov Luminescence

doi: 10.1002/smll.201400733

Figure Lengend Snippet: Octreotate Modified Iron Oxide NP for Targeted Cerenkov Quenching. OCT-Cy5.5-SPIO were administered to mice bearing bilateral xenografts with (C6 hSSTr2) or without (C6 WT) hSSTr2 expression. (A) The fluorescent nanoparticles demonstrate the specific uptake of this new probe at the positive, hSSTR2-expressing, tumor. (B) Prior to nanoparticle administration, 11.1 MBq of [18F]-FDG was given for PET and CL imaging. Greater glycolytic activity in the hSSTr2+ tumor CL of a representative animal is presented in left and right sagittal views with axial PET through the tumors. CL when normalized for percent injected dose per gram of [18F]-FDG, is not significantly different between the two tumor types. (C) One day following dosing with Cy5.5-SPIO-OCT, the imaging was repeated. Now we are able to again obtain the quantitative information from functional PET imaging, but with the targeted quenching NP we are also able to add a layer of molecularly specific information to distinguish the tumors.

Article Snippet: Nanoparticle Probes Ferumoxyol (Feraheme; AMAG Pharmaceuticals, Inc.) was used as provided.

Techniques: Modification, Expressing, Imaging, Activity Assay, Injection, Functional Assay